← all events raw scan snapshot Feb 5, 2026 — prices as of scan date, not live 75 rows · screens, not recommendations superseded by2026-04-26-biotech-scan ported fromresearch/classic/scans/_archive/2026-02-05-biotech-scan.md scan slugbiotech-scan source typescan-archive
Biotech sector overview - gene editing, mRNA, pharma leaders. Mixed sector: GILD surging, ISRG crashing, gene editing weak.
Quick Snapshot Signal Reading Overall 🟡 MIXED - XBI -1.1% 30D, sector diverging. GILD RSI 93 surging, ISRG RSI 9 crashing. Key insight ISRG RSI 9 is historically extreme -- surgical robotics leader at 6-month lows. GILD +23% 30D breakout. Gene editing CRSP -21% 30D weak, BEAM RSI 26 oversold, EDIT falling knife. Mixed.
Action Matrix Action Stocks Why ✅ STRONG BUY ISRG RSI 9, surgical robotics leader, -20% pullback 📈 ACCUMULATE CRSP, BEAM Gene editing thesis intact, approaching entry zones 🔒 HOLD BIIB, GILD, EXAS, IONS Strong positions or running 🔍 WATCH LLY, BNTX, MRNA, ILMN, INCY, BMRN Wait for better entry or clarity ⚠️ AVOID IBRX, NTLA, GILD (new buys) IBRX extended, NTLA speculative, GILD overbought ❌ DON'T BUY EDIT, LEGN, BLUE Falling knives, structural weakness
Sector Overview ETF/Index Price 7D 30D RSI Status XBI $120.72 - -1.1% 43 🟡 Slightly weak LABU (3x bull) $149.04 -14.6% -6.4% 42 🟡 Pullback LABD (3x bear) $21.00 +14.6% +0.0% 56 🟡 Rising
Pattern: Biotech showing relative strength vs tech (XBI -1% vs QQQ -4%), but not immune. Flight to quality pharma (GILD , BIIB ) over speculative biotech.
Data (Validated 2026-02-05) Stock Price 7D 30D RSI Status Action GILD $149.37 +7.0% +23.1% 93 ↑ 🔴 OVERBOUGHT ⚠️ Don't chase BIIB $185.36 +5.2% +1.5% 73 ↑ 🟢 Near highs 🔒 Hold ISRG $476.32 -6.2% -19.7% 9 ↓ 🔴 EXTREME OVERSOLD ✅ ENTRY ZONE LLY $1,020.84 -0.3% -4.1% 48 🟡 Pullback 🔍 Wait for more dip IONS $83.48 -0.5% +2.4% 69 🟢 Near overbought 🔒 Hold EXAS $102.66 +0.4% +1.0% 58 🟢 Steady 🔒 Hold BNTX $105.54 -9.6% +7.6% 49 🟡 Pullback from run 🔍 Watch BMRN $57.15 +0.3% -4.9% 63 🟡 Steady 🔍 Watch MRNA $40.87 -12.8% +14.6% 53 🟡 Pullback from run 🔍 Wait for $35-38 INCY $102.76 +1.7% -3.7% 44 🟡 Sideways 🔍 Watch CRSP $45.88 -14.0% -21.2% 36 🟡 Pullback 📈 Approaching $45 entry ILMN $133.61 -10.7% -9.2% 36 🟡 Pullback 🔍 Research NTLA $11.09 -20.2% +14.0% 46 🟡 Volatile ⚠️ High risk BEAM $24.73 -15.6% -12.7% 26 ↓ 🟡 OVERSOLD 📈 Accumulate zone DNA $8.32 -10.6% -9.3% 38 🟡 Pullback 🔍 Speculative IBRX $5.64 -4.6% +163.6% 63 ⚠️ Extended ⚠️ Too volatile ALNY $331.24 -4.5% -18.5% 35 🟡 Pullback 🔍 Research RNAi leader LEGN $16.70 -5.8% -20.4% 17 ↓ 🔴 EXTREME ❌ Falling knife EDIT $1.66 -19.4% -22.4% 35 🔴 Falling ❌ Don't buy
Category Analysis Pharma Leaders Stock Price 30D RSI Thesis Action GILD $149.37 +23.1% 93 ↑ HIV/HCV franchise + oncology pipeline ⚠️ Overbought, don't chase LLY $1,020.84 -4.1% 48 GLP-1 leader (Mounjaro/Zepbound) 🔍 Wait for $950-1000 entry BIIB $185.36 +1.5% 73 Alzheimer's pipeline 🔒 Hold, near overbought
Surgical/Diagnostics Stock Price 30D RSI Thesis Action ISRG $476.32 -19.7% 9 ↓ Surgical robotics monopoly (da Vinci) ✅ BUY ZONE - RSI 9 extreme EXAS $102.66 +1.0% 58 Cancer screening (Cologuard) 🔒 Hold ILMN $133.61 -9.2% 36 Genomic sequencing leader 🔍 Watch $125 support
mRNA/Vaccines Stock Price 30D RSI Thesis Action MRNA $40.87 +14.6% 53 mRNA pipeline beyond COVID 🔍 Wait pullback to $35-38 BNTX $105.54 +7.6% 49 mRNA + oncology pipeline 🔍 Watch, fading momentum
Gene Editing Stock Price 30D RSI Thesis Action CRSP $45.88 -21.2% 36 Casgevy approved, first CRISPR drug 📈 Near $45 entry zone BEAM $24.73 -12.7% 26 ↓ Base editing technology 📈 Oversold, accumulate NTLA $11.09 +14.0% 46 Liver gene editing pipeline ⚠️ Volatile, speculative EDIT $1.66 -22.4% 35 Sickle cell pipeline ❌ Falling knife, avoid
Specialty Biotech Stock Price 30D RSI Thesis Action ALNY $331.24 -18.5% 35 RNAi therapeutics leader 🔍 Interesting pullback, research IONS $83.48 +2.4% 69 Antisense technology leader 🔒 Hold, approaching overbought LEGN $16.70 -20.4% 17 ↓ CAR-T cell therapy ❌ Falling knife IBRX $5.64 +163.6% 63 Small cap breakout ⚠️ Too extended, FOMO trap
Key Holdings Update CRSP (Existing Position) Metric Value Entry $51.31 Current $45.88 Return -10.6% RSI 36 Status 🟡 Below entry, approaching add zone
Thesis check: Casgevy commercial rollout continues. -21% from 30D ago. Approaching $45 accumulation zone from 02/04 scan.
Action: Consider adding at $45 zone. Hold existing. Stop at $38.
Key Changes vs 02/04 Change Detail ISRG crashed RSI 9 (was not tracked 02/04) -- extreme oversold, surgical robotics leader CRSP fell further $50.17 -> $45.88 (-8.5%), now at target $45 zone BEAM oversold RSI 26, was not flagged 02/04 GILD surging $149.37, RSI 93 -- parabolic, HIV/oncology strength LEGN collapsing RSI 17, -20% 30D, CAR-T thesis failing ALNY big pullback -18.5% 30D, RNAi leader now interesting
Actionable Signals Signal Stock Current Target Action ISRG extreme oversold ISRG $476 (RSI 9) $450-480 ✅ Entry zone NOW CRSP at target CRSP $45.88 $45 📈 Add zone reached BEAM oversold BEAM $24.73 (RSI 26) $22-25 📈 Accumulate ALNY pullback ALNY $331 $300-320 🔍 Research, wait more LLY watch LLY $1,021 $950-1000 🔍 Wait for better entry
The Gold Key Discoveries Discovery Implication ISRG RSI 9 is extreme Surgical robotics monopoly rarely this oversold -- potential generational entry GILD RSI 93 breakout HIV/oncology pipeline driving, but DON'T CHASE at these levels CRSP reached $45 target Entry zone from 02/04 scan hit -- thesis intact Gene editing diverging CRSP/BEAM pullback vs EDIT/LEGN collapse -- quality matters Biotech relative strength XBI -1% vs QQQ -4% -- defensive rotation into healthcare ALNY -18.5% new opportunity RNAi leader pullback, not on previous radar
Mistakes (Don't Repeat) Mistake Lesson Didn't track ISRG earlier Surgical robotics leader should have been on watchlist before RSI 9 IBRX still extended +163% is not an entry -- wait for base building EDIT position sizing Gene editing small caps can go to zero -- size accordingly
Speculative/Research Needed Stock Price 30D RSI Why Risk IBRX $5.64 +163.6% 63 Biotech small cap breakout ⚠️ Extreme extension NTLA $11.09 +14.0% 46 Gene editing competitor ⚠️ Pipeline risk, volatile DNA $8.32 -9.3% 38 Synthetic biology ⚠️ Speculative, burning cash
Commands Biotech overview the desk's own tooling
the desk's own tooling
Individual stocks the desk's own tooling
the desk's own tooling
the desk's own tooling
the desk's own tooling
```
No direct external sources are attached to this read.